These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 28677246)
41. Factor XI Deficiency. Lewandowska MD; Connors JM Hematol Oncol Clin North Am; 2021 Dec; 35(6):1157-1169. PubMed ID: 34535287 [TBL] [Abstract][Full Text] [Related]
42. The clinical management of factor XI deficiency in pregnant women. Wheeler AP; Hemingway C; Gailani D Expert Rev Hematol; 2020 Jul; 13(7):719-729. PubMed ID: 32437625 [TBL] [Abstract][Full Text] [Related]
43. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors. Salomon O; Gailani D J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741 [TBL] [Abstract][Full Text] [Related]
44. Genetic analysis in Factor XI deficient patients from central China: identification of one novel and seven recurrent mutations. Liu H; Wang HF; Tang L; Yang Y; Wang QY; Zeng W; Wu YY; Cheng ZP; Hu B; Guo T; Hu Y Gene; 2015 Apr; 561(1):101-6. PubMed ID: 25681615 [TBL] [Abstract][Full Text] [Related]
45. Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency. Gidley GN; Holle LA; Burthem J; Bolton-Maggs PHB; Lin FC; Wolberg AS Blood Adv; 2018 May; 2(10):1076-1088. PubMed ID: 29760205 [TBL] [Abstract][Full Text] [Related]
46. Intrinsic pathway of coagulation and arterial thrombosis. Gailani D; Renné T Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2507-13. PubMed ID: 17916770 [TBL] [Abstract][Full Text] [Related]
47. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation. Zivelin A; Ogawa T; Bulvik S; Landau M; Toomey JR; Lane J; Seligsohn U; Gailani D J Thromb Haemost; 2004 Oct; 2(10):1782-9. PubMed ID: 15456490 [TBL] [Abstract][Full Text] [Related]
49. Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis. Zhong C; Zhang L; Chen L; Deng L; Li R J Thromb Haemost; 2017 Jan; 15(1):122-130. PubMed ID: 27813324 [TBL] [Abstract][Full Text] [Related]
50. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Broze GJ; Yin ZF; Lasky N Thromb Haemost; 2001 Apr; 85(4):747-8. PubMed ID: 11341518 [No Abstract] [Full Text] [Related]
51. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Kravtsov DV; Wu W; Meijers JC; Sun MF; Blinder MA; Dang TP; Wang H; Gailani D Blood; 2004 Jul; 104(1):128-34. PubMed ID: 15026311 [TBL] [Abstract][Full Text] [Related]
52. Anticoagulant therapy in patients with congenital FXI deficiency. Bravo-Pérez C; Serna MJ; Esteban J; Fernandez-Mellid E; Fontanes-Trabazo E; Lorenzo A; Calviño-Suárez M; Miñano A; Padilla J; Roldán V; Vicente V; Corral J; de la Morena-Barrio ME Blood Adv; 2021 Oct; 5(20):4083-4086. PubMed ID: 34597376 [TBL] [Abstract][Full Text] [Related]
53. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568 [TBL] [Abstract][Full Text] [Related]
54. Phenotype and genotype analysis of patients with severe factor XI deficiency in Shaanxi Province, China. Yuan L; Chen W; Wang X; Zhang H Blood Coagul Fibrinolysis; 2021 Dec; 32(8):539-543. PubMed ID: 34776502 [TBL] [Abstract][Full Text] [Related]